Amivantamab
(Redirected from Rybrevant)
A monoclonal antibody used in cancer treatment
Amivantamab | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Amivantamab is a monoclonal antibody used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically designed to target and inhibit the activity of the epidermal growth factor receptor (EGFR) and MET proto-oncogene proteins, which are often implicated in the development and progression of cancer.
Mechanism of Action[edit | edit source]
Amivantamab is a bispecific antibody that binds to both the EGFR and MET receptors on the surface of cancer cells. By targeting these receptors, amivantamab disrupts the signaling pathways that promote tumor growth and survival. This dual inhibition is particularly beneficial in cases where tumors have developed resistance to other EGFR-targeted therapies.
Clinical Use[edit | edit source]
Amivantamab is primarily used in the treatment of NSCLC with specific genetic mutations, such as exon 20 insertion mutations in the EGFR gene. These mutations are less common but are associated with poor prognosis and limited treatment options. Amivantamab provides a targeted therapy option for patients with these mutations, offering a new avenue for treatment where traditional therapies may have failed.
Administration[edit | edit source]
Amivantamab is administered via intravenous infusion. The dosing schedule typically involves an initial loading phase followed by maintenance doses. The specific regimen may vary based on the patient's condition and response to treatment.
Side Effects[edit | edit source]
Common side effects of amivantamab include skin rash, infusion-related reactions, and paronychia. More serious adverse effects can occur, such as interstitial lung disease and hepatotoxicity, which require careful monitoring and management by healthcare professionals.
Development and Approval[edit | edit source]
Amivantamab was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of NSCLC with EGFR exon 20 insertion mutations, based on clinical trial data demonstrating its efficacy and safety profile.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju, Prab R. Tumpati, MD